Trillium Asset Management LLC decreased its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 2.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 252,788 shares of the biopharmaceutical company’s stock after selling 6,207 shares during the period. Gilead Sciences accounts for about 1.4% of Trillium Asset Management LLC’s investment portfolio, making the stock its 8th largest position. Trillium Asset Management LLC’s holdings in Gilead Sciences were worth $21,088,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the stock. Mn Services Vermogensbeheer B.V. bought a new position in Gilead Sciences during the first quarter worth $2,912,000. Alexandria Capital LLC raised its position in Gilead Sciences by 140.9% in the first quarter. Alexandria Capital LLC now owns 157,674 shares of the biopharmaceutical company’s stock worth $14,484,000 after buying an additional 92,226 shares during the last quarter. Nisa Investment Advisors L.L.C. raised its position in Gilead Sciences by 4.3% in the first quarter. Nisa Investment Advisors L.L.C. now owns 500,421 shares of the biopharmaceutical company’s stock worth $45,969,000 after buying an additional 20,700 shares during the last quarter. Virginia Retirement System bought a new position in Gilead Sciences during the first quarter worth $45,762,000. Finally, Tiemann Investment Advisors LLC raised its position in Gilead Sciences by 14.1% in the first quarter. Tiemann Investment Advisors LLC now owns 4,450 shares of the biopharmaceutical company’s stock worth $409,000 after buying an additional 550 shares during the last quarter. Institutional investors and hedge funds own 78.00% of the company’s stock.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded up 1.06% during trading on Tuesday, hitting $73.41. 6,353,498 shares of the company were exchanged. Gilead Sciences Inc. has a 12 month low of $72.21 and a 12 month high of $111.11. The stock has a market cap of $96.88 billion, a P/E ratio of 6.44 and a beta of 1.10. The company’s 50-day moving average price is $77.59 and its 200 day moving average price is $84.05.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.02 by $0.06. The company had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. Gilead Sciences’s revenue was down 5.7% on a year-over-year basis. During the same quarter last year, the firm posted $3.15 earnings per share. On average, equities analysts predict that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date of this dividend was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is currently 16.56%.

A number of equities analysts have weighed in on GILD shares. Leerink Swann reiterated a “buy” rating and set a $120.00 price objective on shares of Gilead Sciences in a research note on Tuesday, June 21st. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, June 29th. Jefferies Group reiterated a “hold” rating and set a $96.00 price objective on shares of Gilead Sciences in a research note on Wednesday, June 29th. BMO Capital Markets restated an “outperform” rating and set a $97.00 target price on shares of Gilead Sciences in a research report on Wednesday, June 29th. Finally, Credit Suisse Group AG restated a “buy” rating and set a $120.00 target price on shares of Gilead Sciences in a research report on Wednesday, June 29th. Ten investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $102.78.

In other Gilead Sciences news, insider John F. Milligan sold 70,000 shares of the stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the transaction, the insider now owns 1,128,963 shares of the company’s stock, valued at $87,765,583.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider John C. Martin sold 100,000 shares of the stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $77.63, for a total transaction of $7,763,000.00. Following the transaction, the insider now directly owns 3,231,096 shares in the company, valued at approximately $250,829,982.48. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.